Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis

Young Eun Chon, Young-Joo Jin, Jihyun An, Hee Yeon Kim, Miyoung Choi, Dae Won Jun, Mi Na Kim, Ji Won Han, Han Ah Lee, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2024;30(Suppl):S117-S133. Published online August 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0392

View: 848 Download: 83

Special Issue

KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease

Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim

Clin Mol Hepatol. 2024;30(Suppl):S5-S105. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0506

View: 722 Download: 93

Snapshot

Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations

Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen

Clin Mol Hepatol. 2024;30(3):582-584. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0555

View: 6898 Download: 85

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 2007 Download: 140 Web of Science: 4 Crossref: 2

Original Article

Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease

Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(3):449-467. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0047

View: 3406 Download: 340 Crossref: 1

Letter to the Editor

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 2018 Download: 48 Crossref: 1

Original Article

Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study

Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue

Clin Mol Hepatol. 2024;30(2):225-234. Published online January 24, 2024

DOI: https://doi.org/10.3350/cmh.2023.0515

View: 4037 Download: 215 Web of Science: 5 Crossref: 5

Editorial

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2024;30(2):168-170. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0140

View: 2388 Download: 72 Web of Science: 1 Crossref: 2

JCAD, a new potential therapeutic target in cholestatic liver disease

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):166-167. Published online March 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0128

View: 2178 Download: 56 Web of Science: 1 Crossref: 1

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(2):150-153. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0116

View: 3020 Download: 79 Web of Science: 3 Crossref: 2

Snapshot

Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease

Young Chang, Soung Won Jeong, Jae Young Jang

Clin Mol Hepatol. 2024;30(1):129-133. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0356

View: 2854 Download: 156 Crossref: 3

Correspondence

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):124-125. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0470

View: 1717 Download: 43 Web of Science: 1 Crossref: 2

Letter to the Editor

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 2013 Download: 82 Web of Science: 7 Crossref: 7

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji

Clin Mol Hepatol. 2024;30(1):113-117. Published online November 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0440

View: 2064 Download: 71 Web of Science: 2 Crossref: 1

Original Article

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets

Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu

Clin Mol Hepatol. 2024;30(1):80-97. Published online December 7, 2023

DOI: https://doi.org/10.3350/cmh.2023.0343

View: 4548 Download: 206 Web of Science: 3 Crossref: 3

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review

George Chen, Bubu Banini, Albert Do, Joseph K. Lim

Clin Mol Hepatol. 2023;29(Suppl):S319-S332. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0366

View: 3767 Download: 108 Web of Science: 3 Crossref: 4

Review

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0329

View: 5986 Download: 295 Web of Science: 11 Crossref: 12

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3731 Download: 211 Web of Science: 10 Crossref: 14

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 3685 Download: 123 Web of Science: 6 Crossref: 6

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 4018 Download: 137 Web of Science: 5 Crossref: 5

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 8010 Download: 185 Web of Science: 9 Crossref: 12

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 6103 Download: 285 Web of Science: 9 Crossref: 11

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 4319 Download: 231 Web of Science: 9 Crossref: 8

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 4596 Download: 228 Web of Science: 20 Crossref: 21

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 4536 Download: 212 Web of Science: 12 Crossref: 12

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 5812 Download: 219 Web of Science: 10 Crossref: 13

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 5065 Download: 243 Web of Science: 25 Crossref: 26

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 6090 Download: 283 Web of Science: 17 Crossref: 23

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 4703 Download: 179 Web of Science: 30 Crossref: 31

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 13006 Download: 508 Web of Science: 137 Crossref: 162

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |

Viewed By 5240	MAFLD: How is it different from NAFLD?
Viewed By 4998	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4905	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4673	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4650	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 162	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 136	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 120	MAFLD: How is it different from NAFLD?
Cited By 98	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search